← Back to Clinical Trials
Recruiting Phase 3 NCT06425224

Effectiveness and Safety of TENS Therapy for Premature Ejaculation

Trial Parameters

Condition Premature Ejaculation
Sponsor Boston Medical Group
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 129
Sex MALE
Min Age 18 Years
Max Age 62 Years
Start Date 2022-06-15
Completion 2025-06
Interventions
Tens therapyDapoxetine placeboStandard treatment (dapoxetine 30 mg as needed)

Brief Summary

The objective of this clinical trial is to evaluate the effectiveness and safety of transcutaneous posterior tibial nerve stimulation therapy in patients with premature ejaculation. The main question to answer is: Can the effectiveness and safety of transcutaneous electrostimulation of the posterior tibial nerve alone and combined with standard pharmacological treatment be evaluated in men with lifelong premature ejaculation, compared to standard pharmacological treatment with dapoxetine? Patients will: Be randomized in acontrolled clinical trial. Patients with a diagnosis of premature ejaculation who attend Boston Medical Group clinics in Mexico City will be included. Be assigned by randomization to one of three treatment groups: * Group 1: Tens therapy + dapoxetine placebo on demand. * Group 2: Standard treatment (dapoxetine 30 mg as needed) + placebo therapy. * Group 3: Tens therapy + standard treatment (dapoxetine 30 mg as needed).

Eligibility Criteria

Inclusion Criteria: * Primary premature ejaculation according to the definition of the International Society for Sexual Medicine (ISSM-International Society for Sexual Medicine) (30): a) ejaculation always or almost always occurs within the first minute after penetration, b) inability to delay ejaculation in all or almost all penetrations, c) negative personal consequences are generated, such as stress, annoyance, frustration and/or avoidance of sexual intimacy. * Age between 18 and 62 years. * PEDT score greater than 11. * Stable heterosexual relationship for at least 6 months with interest in maintaining it for at least the duration of the study. * Sexual activity at least once a week. * Minimum chronicity of PD of 6 months. * Voluntary participation in the study. * Signing of the informed consent prior to participation in the study. Exclusion Criteria: * IIEF-EF score less than 26. * Glaucoma * Clinically significant comorbidity: cardiovascular, hepatic, thromboembolic, neurological

Related Trials